Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Significance of MRD in CLL

Tanya Siddiqi • 28 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Venetoclax
CLL14

Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, explores the use of minimal residual disease (MRD) testing in the clinic for chronic lymphocytic leukemia (CLL) patients, and its use in determining the endpoint for treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Tanya Siddiqi

0:59
The potential of combination therapies to improve CAR-T outcomes in patients with CLL
Tanya Siddiqi • 10 Dec 2023
0:54
A research update in Richter's transformation from ASH 2023
Tanya Siddiqi • 10 Dec 2023
3:12
Liso-cel in R/R CLL: 24-month follow-up of TRANSCEND-CLL-004
Tanya Siddiqi • 10 Dec 2023
Novel therapies in NHL: BTK inhibitors & degraders
Nirav Niranjan Shah et al. • 17 Oct 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals